Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 May;6(1):1-2.
doi: 10.3121/cmr.2008.791.

A potential means of investigating the role of luteinizing hormone in the pathogenesis of Alzheimer disease

James S Welsh
Comment

A potential means of investigating the role of luteinizing hormone in the pathogenesis of Alzheimer disease

James S Welsh. Clin Med Res. 2008 May.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Webber KM, Perry G, Smith MA, Casadesus G. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007;5:177–183. - PMC - PubMed
    1. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007;7:300–303. - PubMed
    1. ClinicalTrials.gov. Antigonadotropin-Leuprolide in Alzheimer Disease Drug INvestigation (ALADDIN) VP 104 Study. Available at: http://clinicaltrials.gov/ct/show/nct00076440?orden=6. Last accessed March 21, 2008.
    1. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–1290. - PubMed
    1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–106. - PubMed

MeSH terms